#United States #Various #Alzheimer's Disease #Xanamem #Actinogen

A Groundbreaking Opportunity for Alzheimer's Treatment

Actinogen Medical Limited (ASX: ACW) has announced an exciting opportunity for those affected by Alzheimer's disease, as their pivotal clinical trial, XanaMIA, officially opens for participant enrollment across the United States. This significant phase 2b/3 trial studies the effects of a novel oral medication, Xanamem, compared to a placebo over a timeframe of 36 weeks, followed by a chance for participants to continue on the actual medication for an extended period of up to 24 months.

What is Xanamem?

Xanamem represents a breakthrough in the treatment landscape for Alzheimer’s disease. It works by inhibiting the production of cortisol, a stress hormone linked to cognitive decline, especially in areas of the brain associated with memory and critical thinking. By targeting the synthesis enzyme 11β-HSD1, Xanamem promises to offer a method of controlling cortisol levels without interfering with natural production by the adrenal glands.

The XanaMIA Trial

The XanaMIA trial is open to individuals aged 50 and older who have been diagnosed with mild to moderate Alzheimer's disease. If you or your loved one fits this criteria, you could potentially join many others in a study that could redefine how we manage this condition. Participants will consume one daily tablet of Xanamem or a placebo, with routine clinic visits planned to monitor progress and evaluate cognitive function improvements. Notably, there are no complex procedures involved, like frequent brain scans or lumbar punctures, making participation more accessible.

At the end of the initial trial period, enrolled participants can transition into Actinogen's open-label extension trial, leading to up to 24 months of follow-up treatment with the active medication. This possibility underscores the commitment of Actinogen Medical to not only find answers but to make potential treatments available to those who could benefit.

Enrollment and Eligibility

For those interested, various eligibility criteria do apply. A crucial requirement is that participants must have a study partner accompanying them for clinic visits. Those keen to explore their potential eligibility can visit the clinical trials website or reach out directly to Actinogen’s team for further information.

_For more details, check out the following resources:_

Eligibility Information: Check Eligibility

Trial Website: Actinogen's Trial Page

About Actinogen Medical

Based in Sydney, Australia, Actinogen Medical is dedicated to innovating treatments for Alzheimer's disease and depression through its promising investigational product Xanamem. Having undergone eight clinical trials with over 400 participants, Xanamem has shown potential in managing both cognitive decline and depressive symptoms, marking a significant advancement in psychiatric and neurological health.

The company is focused on continuous research, operational expansion, and providing new therapies that can positively impact many lives battling these challenging conditions. As the XanaMIA trial progresses, Actinogen remains steadfast in its mission to forward scientific research that could fundamentally alter the outlook for individuals facing Alzheimer's disease.

Actinogen Medical calls upon individuals and families affected by Alzheimer's to consider participating in this transformative opportunity. Together, they may help pave the way for a future where Alzheimer's disease is managed more effectively than ever before.

For any inquiries or further engagement regarding the trial, feel free to reach out to Actinogen's dedicated team via their clinical trials email or explore their official website for updates and resources.

Note: Participation in clinical trials involves adhering to specific protocols, and all treatments remain investigational until fully approved by regulatory bodies.